Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TRASTUZUMAB DERUXTECAN Cause Disease progression? 87 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 87 reports of Disease progression have been filed in association with TRASTUZUMAB DERUXTECAN (Enhertu). This represents 3.2% of all adverse event reports for TRASTUZUMAB DERUXTECAN.

87
Reports of Disease progression with TRASTUZUMAB DERUXTECAN
3.2%
of all TRASTUZUMAB DERUXTECAN reports
29
Deaths
14
Hospitalizations

How Dangerous Is Disease progression From TRASTUZUMAB DERUXTECAN?

Of the 87 reports, 29 (33.3%) resulted in death, 14 (16.1%) required hospitalization, and 1 (1.1%) were considered life-threatening.

Is Disease progression Listed in the Official Label?

Yes, Disease progression is listed as a known adverse reaction in the official FDA drug label for TRASTUZUMAB DERUXTECAN.

What Other Side Effects Does TRASTUZUMAB DERUXTECAN Cause?

Death (384) Off label use (258) Nausea (251) Myelosuppression (242) Fatigue (186) Malignant neoplasm progression (171) Vomiting (140) Diarrhoea (132) Interstitial lung disease (130) Pneumonitis (125)

What Other Drugs Cause Disease progression?

RITUXIMAB (7,282) CYCLOPHOSPHAMIDE (7,100) DOXORUBICIN (6,165) VINCRISTINE (5,252) PREDNISONE (5,096) BEVACIZUMAB (4,653) DEXAMETHASONE (4,545) CARBOPLATIN (4,538) CAPECITABINE (3,808) ETOPOSIDE (3,776)

Which TRASTUZUMAB DERUXTECAN Alternatives Have Lower Disease progression Risk?

TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DKST TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-DTTB TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB EMTANSINE TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-PKRB TRASTUZUMAB DERUXTECAN vs TRASTUZUMAB-QYYP

Related Pages

TRASTUZUMAB DERUXTECAN Full Profile All Disease progression Reports All Drugs Causing Disease progression TRASTUZUMAB DERUXTECAN Demographics